Abstract: The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals.

Abstract: The present invention provides a process for the preparation of a compound of formula (I): wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl; the process comprising either: a. hydrogenating a compound of formula (II): with a suitable transition metal catalyst in a C1-6 aliphatic alcohol, an ether, an ester or a hydrocarbon as solvent; or, b. conducting a one-pot hydrogenation of a compound of formula (III): wherein R2 is phenyl optionally substituted by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N; i. firstly at about 20° C. to form a compound of formula (IV): ii. and then at about 40° C.; both steps (i) and (ii) being carried out in the presence of a suitable catalyst and in the presence of a suitable solvent.

Abstract: The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals.

Abstract: The invention relates to a novel process for the preparation of certain cyclopropyl carboxylic acid esters and other cyclopropyl carboxylic acid derivatives; a novel process for the preparation of dimethylsulfoxonium methylide and dimethylsulfonium methylide; to the use of certain cyclopropyl carboxylic acid esters in a process for the preparation of intermediates that can be used in the synthesis of pharmaceutically active entities; and to certain intermediates provided by these processes.

Abstract: The invention relates to a novel process for the preparation of certain cyclopropyl carboxylic acid esters and other cyclopropyl carboxylic acid derivatives; a novel process for the preparation of dimethylsulfoxonium methylide and dimethylsulfonium methylide; to the use of certain cyclopropyl carboxylic acid esters in a process for the preparation of intermediates that can be used in the synthesis of pharmaceutically active entities; and to certain intermediates provided by these processes.

Abstract: Pyrimidine compound (I) useful as a pharmaceutical intermediate, a process for preparing the pyrimidine compound (I), to intermediates used in the process, and use of the pyrimidine compound (I) in the preparation of pharmaceuticals. The process comprises hydrogenating a compound of formula (IV): wherein Ar is a phenyl optionally substituted by halogen, C1-4 alkyl or C1-4 alkoxy; to give a compound of formula (II): and reacting the compound of formula (II) with a salt of a compound of formula (III): to provide the compound of formula (I).

Abstract: The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals.

Abstract: An access system (ACC1) for relating communication service providers (SP1-SPn) and application service providers (AS) to users (U11-Um1) includes an edge access server (EAS) connecting the service providers and penults (P1-Pk) connecting the users. User devices (UD11-UD14) are connected via VLAN:s to user port (UP11) on the penult. Service agents (SA1-San, ASA), an administrator (AD1), a broadcast handler (BH1) and handlers (H1-Hk) in the penults form a handling system. A user (U11) decision including VLAN, service (SP1) and user port (UP11) is sent to the administrator (AD1), which dynamically allocates to the relevant service agent (SA1) a MAC address, defining a relation (r11). A user device (UD11) broadcasts an ARP request to get the MAC address to teh service agent (SA1). A service access relation to the application service provider (AS) is provided such that it can be reached by users having relations (R11, R21) to the communication service providers (SP1-SPn).

Abstract: An access system (ACC1) for relating service providers (SP1-SPn) to users (U11-Um1) includes an edge access server (EAS) connecting the service providers and penults (P1-Pk) connecting the users. User devices (UD11-UD14) are connected via VLAN:s to a user ports (UP11) on the penult. The edge access server has service agents (SA1-SAn), an administrator (AD1) and a broadcast handler (BH1), which forms a handling system together with handlers (H1-Hk) in the penults. A user (U11) decision including VLAN, service (SP1) and user port (UP11) is sent to the administrator (AD1), which dynamically allocates to the relevant service agent (SA1) a MAC address, defining a relation (R11). A user device (UD11) broadcasts a DHCP request unicasted together with user port (UP11) to the braoadcast handler (BH1). The user device (UD11) gets its IP address and IP address to the service agent (SA1). The device (UD11) broadcasts an ARP request which is unicasted by the penult (P1), to get the MAC address to the service agent (SA1).

Abstract: An access system (ACC1) for relating service providers (SP1-SPn) to users (U11-Um1) includes an edge access server (EAS) connecting the service providers and penults (P1-Pk) connecting the users. User devices (UD11-UD14) are connected via VLAN:s to a user port (UP11) on the penult. The edge access server has service agents (SA1-SAn), an administrator (AD1) and a broadcast handler (BH1), which forms a handling system together with handlers (H1-Hk) in the penults. A user (U11) decision including VLAN, service (SP1) and user port (UP11) is sent to the administrator (AD1), which dynamically allocates to the relevant service agent (SA1) a MAC address, defining a relationship (R11). A user device (UD11) broadcasts a DHCP request unicasted together with user port (UP11) to the broadcast handler (BH1). The user device (UD11) gets its IP address and IP address to the service agent (SA1).

Abstract: An integrated process for preparing &agr;-(2,4-disulfophenyl)-N-tert-butylnitrone and its salts is disclosed in which N-tert-butylhydroxylamine acid addition salt is incompletely neutralised so as to leave catalytic amounts of acid and the neutralisation product is condensed with an appropriate aldehyde.

Abstract: The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals.

Abstract: The invention relates to a novel process for the preparation of certain cyclopropyl carboxylic acid esters and other cyclopropyl carboxylic acid derivatives; a novel process for the preparation of dimethylsulfoxonium methylide and dimethylsulfonium methylide; to the use of certain cyclopropyl carboxylic acid esters in a process for the preparation of intermediates that can be used in the synthesis of pharmaceutically active entities; and to certain intermediates provided by these processes.

Abstract: An integrated process for preparing &agr;-(2,4-disulfophenyl)-N-tert-butylnitrone and its salts is disclosed in which N-tert-butylhydroxylamine acid addition salt is incompletely neutralised so as to leave catalytic amounts of acid and the neutralisation product is condensed with an appropriate aldehyde.

Abstract: The present invention relates to a novel monophosphate salt of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine. Moreover, the present invention also relates to a process for the preparation of the monophosphate salt of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine as well as a pharmaceutical formulation containing it and its use in medicine.